— Know what they know.
Not Investment Advice

DNTH

Dianthus Therapeutics, Inc.
1W: -0.0% 1M: +56.6% 3M: +87.9% YTD: +96.2% 1Y: +278.1% 3Y: +554.8% 5Y: -62.5%
$77.76
-2.24 (-2.80%)
After Hours: $74.92 (-2.84, -3.65%)
NASDAQ · Healthcare · Biotechnology · $2.8B · Alpha Radar Strong Buy · Power 65
Smart Money Score
Moderate 50
Insider+$51.8M
Congress
ETF Holdings
Key Statistics
Market Cap$2.8B
52W Range13.37-88.02
Volume2,414,473
Avg Volume950,964
Beta1.24
Dividend
Analyst Ratings
10 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOMarino Garcia
Employees78
SectorHealthcare
IndustryBiotechnology
IPO Date2018-06-21
7 Times Square
New York City, NY 10036
US
929-999-4055
About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Recent Insider Trades

NameTypeSharesPriceDate
Garcia Marino M-Exempt 59,700 $6.70 2026-03-16
Garcia Marino M-Exempt 5,592 $17.88 2026-03-16
Garcia Marino M-Exempt 59,700 $6.70 2026-03-16
Garcia Marino M-Exempt 5,592 $17.88 2026-03-16
Garcia Marino M-Exempt 122,918 $6.70 2026-03-12

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms